Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.

An ingestible device is disclosed which can produce spectral data of one or more analytes, as well as associated methods for characterizing the gastrointestinal tract of a subject which contains such analytes. Related kits and systems are also disclosed.

An ingestible device is disclosed which can produce spectral data of one or more analytes, as well as associated methods for characterizing the gastrointestinal tract of a subject which contains such analytes. Related kits and systems are also disclosed.

An ingestible device is disclosed which can produce spectral data of one or more analytes, as well as associated methods for characterizing the gastrointestinal tract of a subject which contains such analytes. Related kits and systems are also disclosed.

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.